MetaCap

Nuvectis Pharma (NVCT) vs Obsidian Therapeutics (OBX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Obsidian Therapeutics is the larger company by market cap ($741.3 million vs $666.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVCT-0.77%OBX-31.43%
+107%+27%-52%
Jul 27, 20261 yearNov 20, 2026
NVCT-9.90%OBX-23.18%
+81%+26%-30%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVCT versus OBX key metrics
MetricNVCTOBX
Share price$19.39$12.00
Market cap$666.80M$741.29M
1-day change-2.27%-1.23%
YTD return+156.82%—
1-year return+218.91%—
EPS (TTM)$-2.00$-6.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-26.44M—
52-week high$29.28$49.97
52-week low$5.77$9.60
Distance from 52-week high-33.77%-75.99%
Analyst consensusnonestrong_buy
Avg. price target upside+82.57%+222.25%
Average volume206.37K511.50K
Shares outstanding34.39M61.77M
Employees1987
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Obsidian Therapeutics

OBX stock →

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

NVCT vs OBX FAQ

Which is bigger, Nuvectis Pharma or Obsidian Therapeutics?

Obsidian Therapeutics (OBX) is larger, with a market capitalization of $741.29M compared with $666.80M for Nuvectis Pharma (NVCT).

Are Nuvectis Pharma and Obsidian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons